# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
LEQEMBI is now approved in the U.S., Japan and China, and applications have been submitted for review in the European Union, Au...
Jim Cramer recommends buying Micron, adding that he likes the company's CEO Sanjay Mehrotra. As for Fidelis? "Not a fav...
HSBC analyst Morten Herholdt maintains Biogen (NASDAQ:BIIB) with a Buy and raises the price target from $339 to $342.
Oppenheimer analyst Jay Olson maintains Biogen (NASDAQ:BIIB) with a Outperform and maintains $270 price target.
With the earnings season now halfway through, the percentage of S&P 500 companies reporting positive earnings surprises and...
Barclays analyst Carter Gould maintains Biogen (NASDAQ:BIIB) with a Equal-Weight and lowers the price target from $215 to $200.